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FIG E1. Exposure to mouse and dust mite allergen is associated with more baseline symptoms but not with
higher acute exacerbation severity. Subjects sensitized (specific IgE >_ 0.35 kU/L) and exposed to (A)mouse
allergen (Mus m1, >_0.5 mg/g of dust, n5 79) or (B) dust mite allergen (Der f1, >_2.0 mg/g of dust, n5 60) in the
bedroom demonstrate worse baseline Asthma Control Questionnaire scores as the degree of allergen sensi-
tization increases than do subjects not exposed to these allergens (mouse, n5 39; dust mite, n5 37). How-
ever, subjects exposed to (C)mouse allergen (n 5 54) or (D) dust mite (n 5 39) allergen in the bedroom do
not have more severe rhinovirus-triggered asthma exacerbations, compared with subjects not exposed to
these allergens (mouse, n 5 25; dust mite, n 5 23). Linear regression coefficients, 95% CIs, and P values for
the interaction between allergen exposure status and IgE levels are shown (multivariate analyses adjusted
for age, sex, race, annual income, lung function, baseline asthma severity, symptom duration, medication
adherence, total number of ImmunoCAP positives, and season). ACQ, Asthma Control Questionnaire; coef,
coefficient.
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FIG E2. Q 19Validation data for the Acute Severity Score.A, Comparison of Acute Severity Scores determined by
2 different groups of observers, respiratory therapists (RTs) and physicians (n5 36). B, Distribution of Acute
Severity Scores (n5 155). C, Receiver operator characteristic curve for Acute Severity Score compared with
ICU admission. The area under the curve 5 90%. D, Comparison of Acute Severity Scores to other out-
comes. P values for continuous and categorical variables determined by t test or Pearson chi-square test,
respectively.
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TABLE E1. Summary of viral infections
Infection % Total enrollment (n)
Rhinovirus/enterovirus 52 (95)
hRV-A (% hRV total) (48%)
hRV-B (% hRV total) (12%)
hRV-C (% hRV total) (40%)
Influenza (A or B) 2 (4)
Human metapneumovirus 3 (5)
Parainfluenza (1, 2, or 3) 5 (9)
Respiratory syncitial virus 3 (6)
Multiple viruses 2 (4)
Negative 33 (60)
hRV, nnnQ 11
The results for all 183 enrolled subjects are shown. Only rhinovirus single-positive
subjects (n 5 95) and control subjects (negative for all tested viruses, n 5 60) were
used for further analysis.
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TABLE E2. Characteristics of virus-negative and rhinovirus-positive subjects
Characteristic Total Virus2 hRV1 P value*
Enrolled, n (% total) 155 (100) 60 (38.7) 95 (61.3) NA
Age (y), mean 6 SD 9.9 6 3.2 10.3 6 3.1 9.7 6 3.2 .321
Sex: male, n (%) 103 (66.5) 42 (70) 61 (64.2) .489
Ethnicity, n (%)
Black/African 75 (48.4) 28 (46.7) 47 (49.5) .745
Hispanic 35 (22.6) 16 (26.7) 19 (20.0) .43
White/European 35 (22.5) 13 (21.6) 22 (23.1) .43
Other 10 (6.5) 3 (5.0) 7 (7.4) .742
BMI, mean 6 SD 21.7 6 5.3 21.9 6 5.2 21.6 6 5.3 .733
Hospital disposition, n (%)
Discharged 64 (41.2) 33 (55.0) 28 (29.5) .002
Hospital admission 91 (58.7) 27 (45.0) 67 (70.5) .002
ICU admission 50 (32.2) 10 (16.7) 40 (42.1) .001
Baseline lung function, mean 6 SD
FEV1, % predicted 99.7 6 14.7 98.6 6 13.0 100.5 6 15.8 .425
FEV1/FVC 84.4 6 6.3 83.8 6 5.9 84.8 6 6.6 .33
Maternal asthma, n (%) 67 (43.2) 24 (40) 43 (45.3) .618
Composite severity, mean 6 SD 7.5 6 3.1 7.4 6 2.7 7.5 6 3.0 .921
Adherence scale, mean 6 SD 4.0 6 0.9 3.9 6 0.9 4.0 6 0.9 .652
Lapsed prescription, n (%)§ 86 (55.5) 30 (50.0) 56 (59.0) .321
Symptom duration (h), mean 6 SDjj 40.5 6 33.8 40.2 6 32.4 40.6 6 34.9 .937
ImmunoCAP positives, mean 6 SDjj 4.3 6 2.4 4.1 6 2.4 4.4 6 2.4 .506
Allergen sensitization, n (%)
Mouse 121 (78.0) 50 (83.3) 71 (74.7) .237
Dust mite 103 (66.5) 44 (73.3) 59 (62.1) .166
Alternaria 28 (18.1) 9 (15.0) 19 (20.0) .523
Aspergillus 43 (27.7) 15 (25.0) 28 (29.5) .585
Cat 117 (76.0) 44 (74.6) 73 (76.8) .847
Dog 121 (78.1) 44 (73.3) 77 (81.1) .32
Mixed grasses 59 (38.1) 22 (36.7) 37 (39.0) .866
Cockroach 43 (27.7) 23 (38.3) 20 (21.1) .027
Total IgE (U/mL), mean 6 SD 614 6 801 608 6 730 617 6 847 .944
Eosinophils (103 cells/mL), mean 6 SD 0.43 6 0.47 0.42 6 0.38 0.43 6 0.53 .915
ETS exposure (ever), n (%) 89 (57.4) 37 (61.7) 52 (54.7) .41
Allergen exposure, %
Mouse{ 66.9 60.9 70.1 .681
Dust mite# 61.9 61.8 61.9 .83
Annual income >$25K, n (%) 111 (72) 45 (75.0) 69 (70) .584
Season (of exacerbation), n (%)
Spring 51 (32.9) 18 (30.0) 33 (34.7) .601
Summer 33 (21.3) 11 (18.3) 22 (23.2) .549
Fall 47 (30.3) 20 (33.3) 27 (28.4) .591
Winter 24 (15.5) 11 (18.3) 13 (13.7) .497
Meters to major road, mean 6 SD 694 6 607 662 6 634 713 6 592 .622
BMI, Body mass index; FVC, forced vital capacity; hRV, nnn; NA, not available/applicable.
*t test or Pearson chi-square test for continuous and categorical variables, respectively.
Composite Asthma Severity Index.E19
Medication Adherence Report Scale for Asthma.E18
§More than 60 d without filling controller prescription.
jjMore than 0.35 kU/L.
{A total of 118 dust samples collected, exposure defined as >_0.5 mg Mus m1/g of dust.
#A total of 97 dust samples collected, exposure defined as >_2.0 mg Der f1/g of dust.
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Coefficient 95% CI P value
Rhinovirus infection 3.65 2.32 4.98 <.001
Age (y) 20.11 20.34 0.11 .320
Sex: male 20.46 21.96 1.03 .543
Ethnicity
Black/African 20.61 22.02 0.80 .395
Hispanic 21.23 22.91 0.45 .149
White/European 2.01 0.35 3.67 .018
BMI 20.06 20.20 0.07 .372
Lung function
FEV1 (% predicted) 20.09 20.13 20.04 <.001
FEV1/FVC 20.19 20.29 20.08 .001
Maternal asthma 0.17 21.25 1.60 .810
Composite severity 0.07 20.16 0.30 .562
Adherence scale 20.04 20.93 0.85 .928
Expired prescription§ 2.97 1.63 4.31 <.001
Symptom duration (h) 0.04 0.02 0.06 <.001
ImmunoCAP positivesjj 0.72 0.45 0.98 <.001
Specific allergen IgE (kU/L){
Mouse 0.04 0.02 0.07 .001
Dust mite 0.09 0.06 0.11 <.001
Alternaria 0.07 20.04 0.17 .210
Aspergillus 0.01 20.16 0.19 .877
Cat 0.00 20.02 0.01 .631
Dog 0.00 20.02 0.03 .701
Mixed grasses 0.03 20.02 0.08 .241
Cockroach 0.05 20.02 0.11 .140
Total IgE (U/mL) 0.00 0.00 0.00 .284
Eosinophils (103 cells/mL) 0.55 20.95 2.05 .468
ETS exposure (ever) 20.94 22.37 0.48 .192
Allergen exposure
Mouse# 20.04 21.96 1.87 .966
Dust mite** 20.06 22.09 1.96 .951
Annual income >$25K 20.32 21.89 1.24 .684
Season (of exacerbation)
Spring 0.30 21.21 1.80 .699
Summer 0.57 21.15 2.30 .512
Fall 0.36 21.18 1.90 .646
Winter 21.81 23.74 0.12 .066
Meters to major road 0.00 0.00 0.00 .402
BMI, Body mass index; ETS, nnnQ 13 ; FVC, forced vital capacity.
*nnnQ 14
Composite Asthma Severity Index.E19
Medication Adherence Report Scale for Asthma.E18
§More than 60 d without filling controller prescription.
jjhRV1 subjects only (omalizumab therapy, n 5 16; standard therapy, n 5 79).
{More than 0.35 kU/L.
#A total of 118 dust samples collected, exposure defined as >_0.5 mg Mus m1/g of dust.
**A total of 97 dust samples collected, exposure defined as >_2.0 mg Der f1/g of dust.Q 15
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TABLE E4. Univariate linear regression of continuous outcome measures related to acute severity*
MPIS PEF, % predicted Time to q2hr albuterol Hospital length of stay
Coef. 95% CI P value Coef. 95% CI P value Coef. 95% CI P value Coef. 95% CI P
Rhinovirus infection 2.76 1.66 3.87 <.001 216.19 222.11 210.27 <.001 13.90 8.14 19.66 <.001 21.43 10.53 32.32 <.001
Age (y) 20.08 20.26 0.11 .401 0.72 20.27 1.72 .151 20.09 21.05 0.86 .850 20.74 22.42 0.95 .388
Sex: male 20.43 21.66 0.80 .493 1.76 24.91 8.42 .603 2.79 23.56 23.56 .387 7.02 24.30 18.34 18.339 Q 16
Ethnicity
Black/African 20.46 21.62 0.70 .435 22.11 28.40 4.18 .509 22.63 28.63 3.38 .389 21.80 212.43 8.84 .738
Hispanic 20.99 22.37 0.40 .161 8.63 3.29 17.97 .031 25.93 213.06 1.20 .102 211.31 224.35 1.73 .088
White/European 1.63 0.27 3.00 .019 25.82 214.27 0.63 .072 7.67 0.58 0.58 .034 4.47 27.69 16.64 .467
BMI 20.07 20.18 0.04 .244 0.07 0.10 1.28 .032 20.02 20.60 0.55 .931 20.79 21.73 0.15 .100
Lung function
FEV1 (% predicted) 20.20 20.12 20.05 <.001 0.36 0.16 0.57 .001 20.28 20.48 20.08 .007 20.56 20.89 20.23 .001
FEV1/FVC 20.17 20.25 20.08 <.001 0.69 0.20 1.18 .006 20.34 20.82 0.13 .156 20.07 20.88 0.74 .862
Maternal asthma 0.17 21.00 1.35 .770 23.76 210.09 2.56 .242 1.16 24.91 7.22 .707 6.49 24.18 17.17 .230
Composite severity 0.19 20.01 0.38 .059 0.36 20.65 1.38 .481 0.71 20.37 1.56 .226 0.30 21.47 2.06 .739
Adherence Scale 20.10 20.83 0.62 .779 0.40 23.52 4.32 .838 0.36 23.70 4.43 .860 20.11 26.65 6.43 .973
Expired prescription§ 2.53 1.43 3.62 <.001 29.63 215.78 23.49 .002 9.26 3.39 15.12 .002 6.82 23.85 17.49 .208
Symptom duration (h) 0.03 0.02 0.05 <.001 20.15 20.24 20.06 .001 0.08 20.01 0.17 .074 0.07 20.08 0.22 .368
ImmunoCAP positivesjj 0.63 0.41 0.85 <.001 23.31 24.50 22.12 <.001 2.10 0.91 3.30 .001 2.40 0.37 4.44 .021
Specific allergen IgEjj
Mouse 0.04 0.02 0.06 <.001 20.21 20.31 20.10 .001 0.07 20.03 0.18 .167 0.10 20.09 0.29 .313
Dust mite 0.07 0.05 0.09 <.001 20.39 20.49 20.28 <.001 0.30 0.20 0.41 <.001 0.37 0.19 0.56 <.001
Alternaria 0.06 20.03 0.14 .190 0.00 20.47 0.47 .990 0.10 20.35 0.55 .667 0.20 20.55 0.94 .602
Aspergillus 0.01 20.13 0.16 .856 0.06 20.72 0.83 .885 20.12 20.86 20.86 .741 20.75 22.89 1.39 .488
Cat 0.00 20.02 0.01 .754 0.04 20.04 0.12 .374 20.04 20.12 0.04 .311 20.16 20.29 20.04 .033
Dog 0.01 20.01 0.03 .549 20.01 20.12 0.10 .841 0.05 20.05 0.15 .327 0.00 20.19 0.19 .998
Mixed grasses 0.02 20.02 0.06 .262 0.01 20.21 0.23 .908 0.05 20.17 0.26 .669 20.04 20.34 0.26 .776
Cockroach 0.04 20.01 0.09 .163 20.22 20.49 0.06 .119 0.12 20.14 0.38 .362 0.08 20.35 0.52 .704
Total IgE 0.00 0.00 0.00 .156 0.00 20.01 0.00 .012 0.00 0.00 0.01 .148 0.01 0.00 0.01 .095
Eosinophil count 0.34 20.89 1.57 .586 25.48 212.11 1.15 .104 3.58 22.85 10.01 .274 3.54 26.16 13.24 .470
ETS exposure (ever) 20.80 21.97 0.37 .178 3.99 22.34 10.33 .215 0.22 25.86 6.31 .942 24.48 215.24 6.28 .411
Allergen exposure
Mouse{ 20.22 21.78 1.35 .783 2.54 25.55 10.62 .535 3.68 24.74 12.10 .388 3.22 210.45 16.89 .640
Dust mite# 0.08 21.58 1.74 .923 0.18 28.84 9.21 .968 24.99 214.29 4.31 .289 24.39 218.94 10.17 .549
Annual income >$25K 20.67 21.96 0.61 .302 0.27 26.71 7.25 .939 4.48 22.15 11.11 .184 7.21 25.08 19.50 .247
Season (of exacerbation)
Spring 0.36 20.87 1.60 .561 23.92 210.59 2.75 .247 21.70 28.09 4.69 .600 0.13 211.09 11.36 .981
Summer 0.37 21.05 1.79 .606 20.92 28.61 6.77 .813 3.50 23.82 10.83 .346 5.40 27.55 18.36 .410
Fall 0.34 20.92 1.60 .595 20.91 27.76 5.94 .794 0.84 25.70 7.38 .800 20.40 212.16 11.36 .947
Winter 21.64 23.22 20.05 .043 9.27 0.69 17.85 .034 22.98 211.28 5.32 .480 26.37 220.84 8.10 .384
Meters to major road 0.00 0.00 0.00 .308 0.00 20.01 0.00 .142 0.00 20.01 0.00 .926 0.00 20.01 0.01 .930
BMI, Body mass index; Coef., coefficient; ETS, nnn; FVC, forced vital capacity.
*Aggregate data for all subjects, n 5 155 (unless otherwise noted).
Composite Asthma Severity Index.E19
Medication Adherence Report Scale for Asthma.E18
§More than 60 d without filling controller prescription.
jjMore than 0.35 kU/L.
{A total of 118 dust samples collected, exposure defined as >_0.5 mg Mus m1/g of dust.
#A total of 97 dust samples collected, exposure defined as >_2.0 mg Der f1/g of dust.
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TABLE E5. Univariate logistic regression of binary outcome measures related to acute severity*
Supplemental O2 Hospital admission ICU admission
OR 95% CI P value OR 95% CI P value OR 95% CI P value
Rhinovirus infection 4.53 1.94 10.58 .001 2.92 1.49 5.73 .002 3.64 1.65 8.03 .001
Age (y) 0.94 0.84 1.05 .256 1.01 0.91 1.11 .923 1.00 0.89 1.11 .938
Sex: male 1.27 0.63 2.54 .499 1.20 0.61 2.37 .593 0.97 0.48 1.98 .935
Ethnicity
Black/African 1.91 0.95 3.84 .068 1.06 0.55 2.02 .865 1.24 0.63 2.43 .535
Hispanic 0.16 0.05 0.56 .004 0.71 0.33 1.52 .383 0.45 0.18 1.11 .083
White/European 1.76 0.80 3.86 .160 1.56 0.70 3.47 .277 1.13 0.51 2.50 .771
BMI 0.91 0.84 0.99 .028 1.02 0.96 1.09 .480 0.98 0.92 1.05 .582
Lung function
FEV1 (% predicted) 0.98 0.95 1.00 .084 1.00 0.97 1.02 .699 0.99 0.96 1.01 .279
FEV1/FVC 1.01 0.95 1.06 .794 0.96 0.91 1.01 .119 1.00 0.95 1.05 .963
Maternal asthma 1.09 0.55 2.17 .809 0.93 0.49 1.79 .834 0.64 0.32 1.29 .212
Composite severity 1.14 1.02 1.27 .026 1.12 1.01 1.25 .034 1.17 1.05 1.31 .006
Adherence Scale 1.06 0.69 1.64 .787 1.01 0.67 1.52 .963 0.81 0.53 1.26 .359
Expired prescription 1.27 0.63 2.54 .499 1.22 0.64 2.34 .542 1.03 0.52 2.03 .929
Symptom duration (h)§ 1.00 0.99 1.01 .606 1.00 0.99 1.01 .577 0.99 0.98 1.00 .138
ImmunoCAP positivesjj 1.11 0.96 1.28 .170 1.16 1.01 1.33 .036 1.17 1.01 1.35 .034
Specific allergen IgE, (kU/L)jj
Mouse 1.00 0.99 1.01 .804 1.01 1.00 1.02 .241 1.01 0.99 1.02 .373
Dust mite 1.01 1.00 1.02 .209 1.02 1.00 1.03 .017 1.01 1.00 1.02 .136
Alternaria 1.03 0.98 1.08 .208 1.01 0.96 1.07 .630 1.04 0.98 1.09 .185
Aspergillus 1.02 0.95 1.11 .546 0.98 0.91 1.06 .629 0.99 0.90 1.08 .782
Cat 1.00 0.99 1.01 .480 1.00 0.99 1.01 .648 1.00 0.99 1.01 .813
Dog 1.00 0.99 1.01 .921 1.00 0.99 1.01 .734 1.00 0.99 1.01 .964
Mixed grasses 1.01 0.99 1.03 .301 1.04 0.98 1.09 .195 1.02 0.99 1.04 .124
Cockroach 1.00 0.97 1.03 .858 1.00 0.97 1.03 .872 0.99 0.95 1.02 .485
Total IgE (U/mL) 1.00 1.00 1.00 .337 1.00 1.00 1.00 .707 1.00 0.99 1.00 .380
Eosinophils (103 cells/mL) 1.04 0.51 2.13 .916 1.15 0.55 2.42 .705 1.13 0.56 2.25 .736
ETS exposure (ever) 1.00 0.50 2.00 .996 1.12 0.58 2.15 .733 1.04 0.52 2.05 .920
Allergen exposure
Mouse{ 1.02 0.44 2.39 .961 1.49 0.65 3.41 .345 1.80 0.75 4.28 .187
Dust mite 0.89 0.36 2.20 .803 1.17 0.46 2.94 .745 0.52 0.21 1.27 .151
Annual income > $25K 0.91 0.43 1.93 .799 1.62 0.80 3.29 .181 1.39 0.64 3.00 .404
Season (of exacerbation)
Spring 1.84 0.90 3.75 .094 1.14 0.57 2.27 .708 1.81 0.90 3.66 .098
Summer 0.83 0.35 1.95 .668 1.00 0.45 2.19 .996 0.89 0.39 2.05 .787
Fall 0.83 0.39 1.77 .634 0.83 0.41 1.66 .591 0.73 0.35 1.56 .420
Winter 0.56 0.19 1.60 .276 1.10 0.45 2.69 .840 0.66 0.24 1.78 .410
Meters to major road 1.00 1.00 1.00 .488 1.00 1.00 1.00 .842 1.00 1.00 1.00 .857
BMI, Body mass index; ETS, nnn; FVC, forced vital capacity; OR, odds ratio.
#A total of 97 dust samples collected, exposure defined as >_2.0 mg Der f1/g of dust.
*Aggregate data for all subjects, n 5 155 (unless otherwise noted).
Composite Asthma Severity Index.E19
Medication Adherence Report Scale for Asthma.E18
§More than 60 d without filling controller prescription.
jjMore than 0.35 kU/L.
{A total of 118 dust samples collected, exposure defined as >_0.5 mg Mus m1/g of dust.
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